Clark Estates Inc. NY Sells 71,125 Shares of Indivior PLC (NASDAQ:INDV)

Key Points

• Clark Estates Inc. reduced its stake in Indivior PLC by 27.6%, selling 71,125 shares during the first quarter, bringing its total ownership to 186,275 shares valued at approximately $1.78 million.
• Analysts have given Indivior a consensus rating of "Buy", with Jefferies Financial Group setting a price target of $20.00, while Craig Hallum raised their target price to $22.00.
• Indivior's stock price opened at $17.28 with a market capitalization of $2.38 billion, reflecting a 12-month performance range between $7.33 and $17.54.

Clark Estates Inc. NY decreased its holdings in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 27.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 186,275 shares of the company's stock after selling 71,125 shares during the period. Clark Estates Inc. NY owned about 0.14% of Indivior worth $1,775,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in shares of Indivior in the fourth quarter valued at approximately $36,000. Lazard Asset Management LLC bought a new position in shares of Indivior in the fourth quarter valued at approximately $57,000. Schaper Benz & Wise Investment Counsel Inc. WI bought a new position in shares of Indivior in the first quarter valued at approximately $95,000. Cannon Global Investment Management LLC bought a new position in shares of Indivior in the first quarter valued at approximately $95,000. Finally, Stifel Financial Corp raised its stake in shares of Indivior by 24.0% in the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after acquiring an additional 2,450 shares during the last quarter. Institutional investors own 60.33% of the company's stock.

Analyst Upgrades and Downgrades

INDV has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Indivior in a report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price target for the company. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Finally, Craig Hallum raised their price target on shares of Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a report on Monday, June 30th. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $17.75.

Indivior Price Performance

INDV traded up $0.85 during trading on Friday, reaching $21.05. 5,588,537 shares of the company's stock were exchanged, compared to its average volume of 3,499,157. The company's fifty day moving average price is $14.85 and its 200-day moving average price is $11.90. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $21.09.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. The company had revenue of $302.00 million for the quarter, compared to analysts' expectations of $239.43 million. Indivior had a net margin of 6.65% and a negative return on equity of 85.50%. As a group, analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.